[Human leukocyte antigen polymorphism of HIV infected persons without disease progress for long-term in Henan province, 2011-2016].

Objective: To understand the disease progression and human leukocyte antigen (HLA) gene polymorphism of HIV-infected persons without disease progress for long term, also known as long-term non-progressors (LTNPs), in Henan province. Methods: A retrospective study was conducted in 48 LTNPs with complete detection and follow-up information during 2011-2016 in Henan. Changes of CD(4)(+)T cells counts (CD(4)) and viral load (VL) during follow-up period were discussed. Polymerase chain reaction-sequence-specific oligonucleotide probe (PCR-SSOP) was used for the analyses of HLA-A, HLA-B and HLA-DRB1 alleles between LTNPs and healthy controls. Results: From 2011 to 2016, forty-eight LTNPs showed a decrease of the quartile (P(25)-P(75)) of CD(4) from 601.00 (488.50-708.72)/μl to 494.00 (367.00-672.00)/μl, and the difference was significant (P<0.05). The increase of the quartile (P(25)-P(75)) of log(10)VL from 3.40 (2.87-3.97) to 3.48 (2.60-4.37), but the difference was not significant (P>0.05). HLA polymorphism analysis revealed that HLA-B*13:02 and HLA-B*40:06 were more common in LTNPs (P<0.05), while HLA-B*46:01 and HLA-DRB1*09:01 were more common in healthy controls (P<0.05). Conclusions: The CD(4) of LTNPs in Henan showed a downward trend year by year. HLA-B*13:02 and B*40:06 might be associated with delayed disease progression for HIV infected persons in Henan.目的： 分析河南省HIV感染长期不进展者（LTNP）病程进展及人类白细胞抗原（HLA）基因多态性特征。 方法： 采用回顾性研究，对河南省2011－2016年检测及随访信息完整的48例LTNP进行分析，探讨随访期间CD(4)(+)T淋巴细胞计数（CD(4)）、病毒载量（VL）的变化情况。采用聚合酶链式反应-序列特异性寡核苷酸探针技术（PCR-SSOP）对LTNP及健康对照的HLA-A、HLA-B和HLA-DRB1基因位点多态性进行分析。 结果： 2011－2016年48例LTNP 6次随访检测发现，CD(4)的四分位数从601.00（488.50~708.72）个/μl降低至494.00（367.00~672.00）个/μl，差异有统计学意义（P<0.05）。log(10)VL的四分位数从3.40（2.87~3.97）上升到3.48（2.60~4.37），差异无统计学意义（P>0.05）。HLA基因位点多态性分析显示，HLA-B*13：02、HLA-B*40：06位点多分布在LTNP中（P<0.05），而HLA-B*46：01、HLA-DRB1*09：01在健康对照中常见（P<0.05）。 结论： 河南省LTNP CD(4)有逐年下降的趋势，HLA-B*13：02、HLA-B*40：06等位基因位点可能与延缓本地区LTNP疾病进程有关。.